Enliven Therapeutics, Inc. $ELVN Shares Acquired by Seven Fleet Capital Management LP

Key Points

• Institutional ownership increased significantly: Seven Fleet Capital Management raised its Enliven Therapeutics stake by 40.9% to 365,386 shares, while BlackRock and several other investors also established or expanded positions. Institutions now own 95.08% of the company.
• Shares are trading near their 52-week high: ELVN opened at $59.32, compared with a 52-week range of $14.78 to $62.32, and has a market capitalization of approximately $4.35 billion. The company reported a quarterly loss of $0.49 per share, missing estimates of a $0.39 loss.
• Analyst sentiment remains broadly positive despite insider selling: Eight analysts rate the stock Buy versus one Sell, with an average price target of $75.00. Meanwhile, insiders sold 186,849 shares worth nearly $11 million over the past three months, including substantial sales by the CFO and a director under pre-arranged trading plans.

Seven Fleet Capital Management LP raised its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 40.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 365,386 shares of the company's stock after acquiring an additional 106,103 shares during the period. Enliven Therapeutics accounts for about 3.1% of Seven Fleet Capital Management LP's holdings, making the stock its 6th biggest position. Seven Fleet Capital Management LP owned 0.50% of Enliven Therapeutics worth $18,543,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in Enliven Therapeutics in the 2nd quarter worth about $221,255,000. Vestal Point Capital LP lifted its holdings in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company's stock worth $58,982,000 after acquiring an additional 2,670,000 shares during the period. Siren L.L.C. acquired a new stake in shares of Enliven Therapeutics in the first quarter worth approximately $29,252,000. Jupiter Topco LLC acquired a new stake in shares of Enliven Therapeutics in the second quarter worth approximately $30,617,000. Finally, Affinity Asset Advisors LLC purchased a new stake in Enliven Therapeutics in the first quarter valued at approximately $23,007,000. Hedge funds and other institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $59.32 on Friday. The firm has a 50-day moving average of $55.66 and a two-hundred day moving average of $44.19. The stock has a market cap of $4.35 billion, a P/E ratio of -35.52 and a beta of 0.30. Enliven Therapeutics, Inc. has a 1-year low of $14.78 and a 1-year high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). As a group, equities analysts expect that Enliven Therapeutics, Inc. will post -1.69 earnings per share for the current year.

Insider Buying and Selling at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $58.58, for a total transaction of $352,534.44. Following the completion of the transaction, the chief financial officer directly owned 40,036 shares in the company, valued at approximately $2,345,308.88. This represents a 13.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika Derynck sold 158,795 shares of the firm's stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the sale, the director directly owned 87,373 shares of the company's stock, valued at $5,260,728.33. The trade was a 64.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 186,849 shares of company stock valued at $10,998,857 in the last three months. Corporate insiders own 3.00% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Mizuho upped their price objective on Enliven Therapeutics from $62.00 to $73.00 and gave the stock an "outperform" rating in a report on Tuesday, August 18th. Stifel Nicolaus lifted their target price on Enliven Therapeutics from $80.00 to $82.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Barclays initiated coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They set an "overweight" rating and a $78.00 price target for the company. JonesTrading boosted their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a "buy" rating in a report on Monday, June 29th. Finally, Wall Street Zen downgraded shares of Enliven Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Enliven Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $75.00.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

Want to see what other hedge funds are holding ELVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.